Current state of thrombolytic therapy

Curr Cardiol Rep. 1999 Sep;1(3):212-20. doi: 10.1007/s11886-999-0025-9.

Abstract

More than 200,000 people have been enrolled into clinical trials examining different reperfusion strategies for patients with acute myocardial infarction. Each year approximately 1 million people in the United States experience acute myocardial infarction. Thrombolytic agents, including streptokinase and tissue-type plasminogen activator, activate plasminogen. These agents are often divided into "fibrin-specific" and "non-fibrin-specific" drugs. New thrombolytic agents designed to address several of the shortcomings of existing thrombolytics are in various stages of clinical development.

Publication types

  • Review

MeSH terms

  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / epidemiology
  • Myocardial Reperfusion
  • Plasminogen Activators / therapeutic use
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins / therapeutic use
  • Streptokinase / therapeutic use
  • Survival Analysis
  • Thrombolytic Therapy* / methods
  • Tissue Plasminogen Activator / therapeutic use
  • Urokinase-Type Plasminogen Activator / therapeutic use

Substances

  • Fibrinolytic Agents
  • Recombinant Proteins
  • lanoteplase
  • reteplase
  • Streptokinase
  • Plasminogen Activators
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator
  • saruplase